about
Crossing the line: selection and evolution of virulence traitsHost-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae.Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains.Virulence is positively selected by transmission success between mammalian hosts.Attaching and effacing bacterial effector NleC suppresses epithelial inflammatory responses by inhibiting NF-κB and p38 mitogen-activated protein kinase activation.Genomic O island 122, locus for enterocyte effacement, and the evolution of virulent verocytotoxin-producing Escherichia coli.Pathogenic adaptation of intracellular bacteria by rewiring a cis-regulatory input function.Characterization of the NleF effector protein from attaching and effacing bacterial pathogens.Correct promoter control is needed for trafficking of the ring-infected erythrocyte surface antigen to the host cytosol in transfected malaria parasites.Multiple seropathotypes of verotoxin-producing Escherichia coli (VTEC) disrupt interferon-gamma-induced tyrosine phosphorylation of signal transducer and activator of transcription (Stat)-1.Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte.MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking.Genetic and molecular analysis of GogB, a phage-encoded type III-secreted substrate in Salmonella enterica serovar typhimurium with autonomous expression from its associated phage.Attaching and effacing pathogen-induced tight junction disruption in vivo.Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleEHost-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of EnterobacteriaceaeGene patents in Australia: where do we stand?Patent watch: Australia's highest court decides isolated nucleic acids are not patent eligible
P50
Q21131620-579F0AAF-5446-4744-B827-C9EF80F216ADQ33306722-1FAD896B-C7AD-446C-9749-7F0FED7DF41EQ33378528-7B74832E-6862-433C-8EC8-BBADBF295AE2Q34003664-D1F6B45F-5AEC-4E30-8836-2DF50293FE76Q35191956-63358A5B-A363-4720-A8AB-3FAD87F84630Q36845551-3EA3A338-CDEB-430F-B26F-D66B69ABC441Q37104889-F624A9F6-E137-46B8-9DEF-EFAB764A2F95Q37133792-33071BEF-954A-42FE-98A6-DEE281204B32Q37523796-CCF12353-74B4-4B90-BCB5-E5C1204EA1CEQ40194447-9F797DEC-350D-4E48-A5E4-DBC63C94742FQ44511093-1392DEA5-CAD2-46A3-B4D4-3032E40E2BD8Q47862670-F0CE5BB7-CB33-423D-B1AB-276651841056Q50091536-FBCE8C0E-E8BA-4C00-8AC9-0DEC6089C8B1Q52569423-9C8487CE-11C4-4B3D-AE25-A0D3D3B6A690Q57676051-22BFBA45-EC38-41AA-BD14-24B48EA0582DQ57932930-35651D2F-ECD9-44D7-891D-7C854964830EQ83852316-86C56046-EDED-4B3E-8D96-C90FB6E98ED4Q86699208-FF695A4B-4E3D-404A-AD17-31FB13F624C7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark E Wickham
@nl
Mark E Wickham
@sl
Mark E. Wickham
@en
Mark E. Wickham
@es
type
label
Mark E Wickham
@nl
Mark E Wickham
@sl
Mark E. Wickham
@en
Mark E. Wickham
@es
prefLabel
Mark E Wickham
@nl
Mark E Wickham
@sl
Mark E. Wickham
@en
Mark E. Wickham
@es
P1053
A-1396-2009
P106
P1153
7004981782
P21
P31
P3829
P496
0000-0002-3473-7196